0001662579-24-000028.txt : 20240308
0001662579-24-000028.hdr.sgml : 20240308
20240308192423
ACCESSION NUMBER: 0001662579-24-000028
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240307
FILED AS OF DATE: 20240308
DATE AS OF CHANGE: 20240308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schick Kelly
CENTRAL INDEX KEY: 0001797388
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39567
FILM NUMBER: 24736193
MAIL ADDRESS:
STREET 1: C/O AMAG PHARMACEUTICALS, INC.
STREET 2: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: C4 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662579
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 475617627
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 490 ARSENAL WAY
STREET 2: SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: (617) 231-0700
MAIL ADDRESS:
STREET 1: 490 ARSENAL WAY
STREET 2: SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
wk-form4_1709943848.xml
FORM 4
X0508
4
2024-03-07
0
0001662579
C4 Therapeutics, Inc.
CCCC
0001797388
Schick Kelly
C/O C4 THERAPEUTICS, INC.
490 ARSENAL WAY #120
WATERTOWN
MA
02472
0
1
0
0
Chief People Officer
0
Stock Option (Right to Buy)
37.46
2024-03-07
4
D
0
92000
0
D
2031-01-10
Common Stock
92000
0
D
Stock Option (Right to Buy)
19
2024-03-07
4
A
0
92000
0
A
2031-01-10
Common Stock
92000
92000
D
Stock Option (Right to Buy)
22.71
2024-03-07
4
D
0
78500
0
D
2032-02-13
Common Stock
78500
0
D
Stock Option (Right to Buy)
19
2024-03-07
4
A
0
78500
0
A
2032-02-13
Common Stock
78500
78500
D
On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
25% of the shares underlying this option vested and became exercisable on January 11, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.
The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022.
/s/ Jolie M. Siegel, Attorney-in-Fact
2024-03-08